Screener
Immunome IMNM Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Immunome’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344636
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 17,359 | 14,636 |
| Operating right-of-use assets | 3,942 | 2,978 |
| Restricted cash | 210 | 210 |
| Other long-term assets | 5,424 | 4,587 |
| Total assets | $565,384 | $683,188 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,996 | $3,339 |
Item 1. Financial Statements.
FAQ
- What is Immunome's deferred tax assets and other non-current assets?
- Immunome (IMNM) reported deferred tax assets and other non-current assets of $5.42M in Q2 2026.
- How has Immunome's deferred tax assets and other non-current assets changed year-over-year?
- Immunome's deferred tax assets and other non-current assets increased by 24.6% year-over-year, from $4.35M to $5.42M.
- What is the long-term trend for Immunome's deferred tax assets and other non-current assets?
- Over 2 years (2023 to 2025), Immunome's deferred tax assets and other non-current assets has grown at a 577.3% compound annual growth rate (CAGR), from $100K to $4.59M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about Immunome's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude